REVIEW Naftopidil (Flivas) is an selective alpha1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM. Naftopidil (Flivas) is an antihypertensive agent. Naftopidil (Flivas) binds specifically to alpha 1-adrenoceptors. The Ki values are 58.3 nM for naftopidi. In Japan, naftopidil is being used as a treatment for the bladder outlet obstruction in patients with benign prostatic hyperplasia.
REFERENCES
[1]
Himmel, Herbert M Naftopidil, a novel antihypertensive drug Cardiovascular Drug Reviews (1994), 12(1), 32-47.
[2]
Yuan JinQiu; Liu Yali; Yang ZuYao; Qin Xiwen; Yang KeHu; Mao Chen; The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews Current medical research and opinion (2013), 29(3), 279-87.
[3]
Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H, Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication. Hinyokika Kiyo. 2011 Jan;57(1):7-13.
[4]
Masumori, Naoya Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia Therapeutics and Clinical Risk Management (2011), 7, 227-238.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
